BS_996ZS2A4
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 20.992115637319316
- age_years
- 3.701
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.584
- INTERFERON_ALPHA_RESPONSE+0.571
- ALLOGRAFT_REJECTION+0.509
- E2F_TARGETS+0.494
- MYC_TARGETS_V1+0.491
- MYC_TARGETS_V2+0.490
- MTORC1_SIGNALING+0.452
- INFLAMMATORY_RESPONSE+0.449
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.405
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.391
Top 10 suppressed
- TGF_BETA_SIGNALING-0.244
- HEDGEHOG_SIGNALING-0.224
- UV_RESPONSE_DN-0.222
- PROTEIN_SECRETION-0.197
- BILE_ACID_METABOLISM-0.166
- HEME_METABOLISM-0.156
- MYOGENESIS-0.144
- NOTCH_SIGNALING-0.084
- MITOTIC_SPINDLE-0.047
- PEROXISOME-0.037
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0368 | Med | Medulloblastoma | 0.926 |
| 2 | BSR_02_0048_A10_S104 | — | C | 0.912 |
| 3 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.893 |
| 4 | BS_RSRPX3S8 | Med | Medulloblastoma | 0.886 |
| 5 | SRR6013600 | — | cohortA1 | 0.883 |
| 6 | SRR13311163 | — | — | 0.879 |
| 7 | R261 | — | — | 0.876 |
| 8 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.874 |
| 9 | BS_QX12J6W1 | ATRT | — | 0.874 |
| 10 | TCGA-A2-A0SV-01A-11R-A084-07 | — | C | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.584 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.571 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.509 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.494 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.491 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.452 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.449 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.405 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.391 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.386 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.379 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.346 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.338 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.293 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.283 | Idelalisib | — uncovered |
| COAGULATION | 0.277 | Binimetinib | — uncovered |